Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 7Busulfan 5ruxolitinib 4Methotrexate 4Cyclosporine 4fludarabine phosphate 3Whole-Body Irradiation 2Mycophenolic Acid 2Flow Cytometry 2Cytogenetic Analysis 2Cytarabine 2Cyclophosphamide 2Antilymphocyte Serum 2venetoclax 1sonidegib 1pomalidomide 1pevonedistat 1pelcitoclax 1lestaurtinib 1givinostat hydrochloride 1givinostat 1ethanolamine oleate 1aldesleukin 1Vitamin E 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Topotecan 1Tacrolimus 1Sulfamethoxazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Polycythemia Vera × Liposomes × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡